TY - JOUR
T1 - Optimizing management of acute leukemia in community centers and when to refer
AU - Jillella, Anand P.
AU - Cortes, Jorge E.
AU - Kota, Vamsi K.
N1 - Funding Information:
A.P.J. declares no conflicts of interest. J.E.C. consults with or has an advisory role with Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc., BiolineRx, Bristol-Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer,Takeda, and received research funding from Astellas Pharma (Inst), Bristol-Myers Squibb (Inst), Daiichi Sankyo (Inst), Immunogen (Inst), Jazz Pharmaceuticals (Inst), Merus (Inst), Novartis (Inst), Pfizer (Inst), Sun Pharma (Inst), Takeda (Inst), Tolero Pharmaceuticals (Inst), and Trovagene (Inst). V.K.K. has provided consultancy or in an advisory board role for Novartis and Pfizer.
Publisher Copyright:
© 2020 American Society of Hematology. All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Treatment of acute leukemia has been delivered predominantly in academic and larger leukemia treatment centers with the infrastructure and staff needed to manage patients receiving complex therapeutic regimens and supportive care. However, in recent years, several oral agents and less-myelosuppressive regimens were approved, making it possible for these patients to receive therapy in smaller community hospitals and oncology office practices. In this review, we discuss the optimum community setting, type of patient who can be treated, agents that can be applied, and an appropriate clinical circumstance in which a referral to a tertiary center should be made.
AB - Treatment of acute leukemia has been delivered predominantly in academic and larger leukemia treatment centers with the infrastructure and staff needed to manage patients receiving complex therapeutic regimens and supportive care. However, in recent years, several oral agents and less-myelosuppressive regimens were approved, making it possible for these patients to receive therapy in smaller community hospitals and oncology office practices. In this review, we discuss the optimum community setting, type of patient who can be treated, agents that can be applied, and an appropriate clinical circumstance in which a referral to a tertiary center should be made.
UR - http://www.scopus.com/inward/record.url?scp=85097311166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097311166&partnerID=8YFLogxK
U2 - 10.1182/HEMATOLOGY.2020000096
DO - 10.1182/HEMATOLOGY.2020000096
M3 - Article
C2 - 33275676
AN - SCOPUS:85097311166
SN - 1024-5340
VL - 20
SP - 123
EP - 128
JO - Hematology. American Society of Hematology. Education Program
JF - Hematology. American Society of Hematology. Education Program
IS - 1
ER -